Related Experiment Video

Updated: May 30, 2026

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

Suppression of inflammation by recombinant Salmonella typhimurium harboring CCL22 microRNA

Won Suck Yoon1, Seung Rel Ryu, Seung Seok Lee

  • 1Department of Biotechnology, School of Life Sciences and Biotechnology, Korea University, Seoul, Korea. biokorea@korea.ac.kr

DNA and Cell Biology
|August 10, 2011
PubMed

Insights

This study shows that suppressing the CCL22 gene with microRNA delivered by Salmonella in mice with atopic dermatitis (AD) reduced inflammation. This approach offers a potential new therapy for AD by targeting key inflammatory pathways.

Area of Science:

  • Immunology
  • Genetics
  • Microbiology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition influenced by genetic and environmental factors.
  • Elevated levels of the chemokine CCL22 are linked to AD severity.
  • CCL22 plays a significant role in skin inflammation.

Purpose of the Study:

  • To investigate the potential of microRNA (miRNA)-mediated suppression of the CCL22 gene.
  • To evaluate the therapeutic effects of targeting CCL22 in an AD-like mouse model.

Main Methods:

  • Developed a recombinant Salmonella typhimurium strain (ST-miRCCL22) to deliver CCL22 miRNA.
  • Administered ST-miRCCL22 orally to mice with AD-like inflammation for in vivo gene knockdown.
  • Assessed changes in immune markers including IgE, interleukin-4, interferon-γ, and Th17 cells.

Main Results:

  • Oral administration of ST-miRCCL22 successfully suppressed the CCL22 gene in activated lymphocytes.
  • Treatment led to inhibition of IgE and interleukin-4, and induction of interferon-γ.
  • A significant suppression of Th17 cells was observed in treated atopic mice.

Conclusions:

  • Suppression of the CCL22 gene using Salmonella-delivered miRNA demonstrates anti-inflammatory effects in an AD model.
  • This strategy highlights the therapeutic potential of targeting CCL22 for managing atopic dermatitis.

More Related Videos

A Non-Coding Small RNA MicC Contributes to Virulence in Outer Membrane Proteins in Salmonella Enteritidis06:30

A Non-Coding Small RNA MicC Contributes to Virulence in Outer Membrane Proteins in Salmonella Enteritidis

Published on: January 27, 2021

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity07:09

Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity

Published on: January 7, 2019

Related Concept Videos

Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...